Literature DB >> 26770394

Expression profile and kinetics of cytokines and chemokines in patients with chronic hepatitis C.

Zhen-Qi Han1, Tao Huang1, Yong-Zhi Deng1, Guang-Ze Zhu1.   

Abstract

Cytokines and chemokines play an important role in defense against viral infection and modulating immune response. However, expression prolife of serum cytokines and chemokines, which were associated with the outcome of patients in response to anti-HCV treatment have not been fully elucidated. The current study aimed to determine the expression pattern of cytokines and chemokines in chronic HCV infection and their association with outcome in response to therapy. Seventy-two patients with HCV infection were enrolled, and fifty-one received peg-interferon α-2a and ribavirin therapy for 48 weeks. Thirty-nine cytokines and chemokines were analyzed by Luminex 200 and ELISA. In comparison to healthy individuals, production of IL-8 and IL-10 were increased in chronic hepatitis C patients. In contrast, IFN-γ, IL-7, and IL-15 were remarkably decreased, especially in HCV genotype 1b infection. HCV RNA load is closely associated with IL-10 and IL-15 expressions, and inhibition of HCV replication was accompanied by reduction in IL-10 and elevation in IL-7 and IL-15. Skewed cytokines and chemokines expression existed in chronic HCV infection, and might play an important role in persistent HCV infection. Exploiting the expression pattern of cytokines and chemokines may help to develop a better understanding of the pathogenesis of chronic HCV infection.

Entities:  

Keywords:  Hepatitis C virus; antiviral therapy; chemokine; cytokine

Year:  2015        PMID: 26770394      PMCID: PMC4694294     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  33 in total

Review 1.  Natural regulatory T cells: mechanisms of suppression.

Authors:  Makoto Miyara; Shimon Sakaguchi
Journal:  Trends Mol Med       Date:  2007-01-24       Impact factor: 11.951

Review 2.  Novel therapies for hepatitis C - one pill fits all?

Authors:  Michael P Manns; Thomas von Hahn
Journal:  Nat Rev Drug Discov       Date:  2013-06-28       Impact factor: 84.694

3.  A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus.

Authors:  Ye Zhang; Melissa A Cobleigh; Jian-Qi Lian; Chang-Xing Huang; Carmen J Booth; Xue-Fan Bai; Michael D Robek
Journal:  Gastroenterology       Date:  2011-06-25       Impact factor: 22.682

4.  Cytokine profiles and hepatic injury in occult hepatitis C versus chronic hepatitis C virus infection.

Authors:  N Mousa; W Eldars; H Eldegla; O Fouda; Y Gad; N Abousamra; E Elmasry; M Arafa
Journal:  Int J Immunopathol Pharmacol       Date:  2014 Jan-Mar       Impact factor: 3.219

5.  Imbalance of regulatory T cells and T helper type 17 cells in patients with chronic hepatitis C.

Authors:  Chunqiu Hao; Yun Zhou; Yu He; Chao Fan; Li Sun; Xin Wei; Linxu Wang; Meijuan Peng; Pingzhong Wang; Jianqi Lian; Zhansheng Jia
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

6.  Association of interleukin-15-induced peripheral immune activation with hepatic stellate cell activation in persons coinfected with hepatitis C virus and HIV.

Authors:  Robert D Allison; Antonios Katsounas; Deloris E Koziol; David E Kleiner; Harvey J Alter; Richard A Lempicki; Brad Wood; Jun Yang; Brandie Fullmer; Karoll J Cortez; Michael A Polis; Shyam Kottilil
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

7.  The natural history of hepatitis C virus (HCV) infection.

Authors:  Stephen L Chen; Timothy R Morgan
Journal:  Int J Med Sci       Date:  2006-04-01       Impact factor: 3.738

8.  Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes.

Authors:  K Kakimi; T E Lane; S Wieland; V C Asensio; I L Campbell; F V Chisari; L G Guidotti
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

9.  Expression pattern of serum cytokines in hepatitis B virus infected patients with persistently normal alanine aminotransferase levels.

Authors:  Dengming He; Maoshi Li; Shimin Guo; Peng Zhu; Hongfei Huang; Guohua Yan; Quanxin Wu; Shiqi Tao; Zhaoxia Tan; Yuming Wang
Journal:  J Clin Immunol       Date:  2013-08-17       Impact factor: 8.317

10.  The cytokine and chemokine profiles in patients with hand, foot and mouth disease of different severities in Shanghai, China, 2010.

Authors:  Mei Zeng; Xiaoyan Zheng; Ruicheng Wei; Na Zhang; Kai Zhu; Bin Xu; Chun-Hui Yang; Chun-Fu Yang; Chaoyang Deng; Dongbo Pu; Xiaohong Wang; Ralf Altmeyer; Qibin Leng
Journal:  PLoS Negl Trop Dis       Date:  2013-12-19
View more
  9 in total

1.  IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.

Authors:  C Carlton-Smith; J A Holmes; S Naggie; A Lidofsky; G M Lauer; A Y Kim; R T Chung
Journal:  J Viral Hepat       Date:  2017-12-27       Impact factor: 3.728

2.  Serum Biomarkers for Discrimination between Hepatitis C-Related Arthropathy and Early Rheumatoid Arthritis.

Authors:  Isabela Siloşi; Lidia Boldeanu; Viorel Biciuşcă; Maria Bogdan; Carmen Avramescu; Citto Taisescu; Vlad Padureanu; Mihail Virgil Boldeanu; Anica Dricu; Cristian Adrian Siloşi
Journal:  Int J Mol Sci       Date:  2017-06-19       Impact factor: 5.923

3.  Restoring Inflammatory Mediator Balance after Sofosbuvir-Induced Viral Clearance in Patients with Chronic Hepatitis C.

Authors:  Geórgia Nascimento Saraiva; Natalia Fonseca do Rosário; Thalia Medeiros; Paulo Emílio Côrrea Leite; Gilmar de Souza Lacerda; Thaís Guaraná de Andrade; Elzinandes Leal de Azeredo; Petronela Ancuta; Jorge Reis Almeida; Analúcia Rampazzo Xavier; Andrea Alice Silva
Journal:  Mediators Inflamm       Date:  2018-05-27       Impact factor: 4.711

4.  Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China: An observational study.

Authors:  Xiao-Wei Xu; Xiao-Xin Wu; Ke-Da Chen; Da-Zhi Chen; Hui-Lin Ou; Jun-Wei Su; Hai-Ying Yu; Hang-Ping Yao; Lan-Juan Li
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

5.  The Genetic Profile and Serum Level of IL-8 Are Associated with Chronic Hepatitis B and C Virus Infection.

Authors:  Ednelza da Silva Graça Amoras; William Botelho de Brito; Maria Alice Freitas Queiroz; Simone Regina Souza da Silva Conde; Izaura Maria Vieira Cayres Vallinoto; Ricardo Ishak; Antonio Carlos Rosário Vallinoto
Journal:  Biomolecules       Date:  2021-11-10

6.  Associations between systemic inflammation, mycobacterial loads in sputum and radiological improvement after treatment initiation in pulmonary TB patients from Brazil: a prospective cohort study.

Authors:  Eliene D D Mesquita; Leonardo Gil-Santana; Daniela Ramalho; Elise Tonomura; Elisangela C Silva; Martha M Oliveira; Bruno B Andrade; Afrânio Kritski
Journal:  BMC Infect Dis       Date:  2016-08-05       Impact factor: 3.090

Review 7.  Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges.

Authors:  Haiyan Zeng; Lei Li; Zhouhua Hou; Yapeng Zhang; Zhongxiang Tang; Shuiping Liu
Journal:  Int J Med Sci       Date:  2020-03-15       Impact factor: 3.738

Review 8.  Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review.

Authors:  Ahmed Babiker; Mohamed Hassan; Safwan Muhammed; Gregory Taylor; Bhawna Poonia; Anoop Shah; Shashwatee Bagchi
Journal:  Clin Cardiol       Date:  2019-11-30       Impact factor: 2.882

9.  Immunological Dynamics Associated with Direct-Acting Antiviral Therapies in Naive and Experimented HCV Chronic-Infected Patients.

Authors:  Grenda Leite Pereira; Andréa Monteiro Tarragô; Walter Luiz Lima Neves; Pedro Vieira da Silva Neto; Priscila Sarmento de Souza; Juliana Dos Santos Affonso; Keyla Santos de Sousa; Jéssica Albuquerque da Silva; Allyson Guimarães Costa; Flamir da Silva Victoria; Marilu Barbieri Victoria; Adriana Malheiro
Journal:  Mediators Inflamm       Date:  2019-11-04       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.